Italia Markets closed

Terumo Corp (TUO.BE)

Berlin - Berlin Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
15,90+0,50 (+3,25%)
In data: 08:17AM CEST. Mercato aperto.
Schermo intero
Chiusura precedente15,40
Aperto15,90
Denaro15,60 x 0
Lettera15,90 x 0
Min-Max giorno15,90 - 15,90
Intervallo di 52 settimane11,90 - 18,10
Volume27
Media Volume0
CapitalizzazioneN/D
Beta (5 anni mensile)N/D
Rapporto PE (ttm)N/D
EPS (ttm)N/D
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update

    U.S. Food and Drug Administration (“FDA”) granted Investigational Device Exemption (“IDE”) approval with conditions for Virtue SAB® coronary in-stent restenosis (“ISR”) U.S. pivotal study (in collaboration with Terumo Corporation (“Terumo”)); study expected to start before the end of 2023BackBeat CNT™ global pivotal study in hypertensive pacemaker patients (in collaboration with Medtronic) on track for initiation in the second half of 2023 NEW HOPE, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Orchest

  • GlobeNewswire

    Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis

    Virtue® Sirolimus AngioInfusion Balloon (“SAB”) is the only non-coated angioplasty system providing protected delivery of extended release sirolimus under clinical investigation worldwideVirtue ISR-US pivotal study focused on coronary in-stent restenosis (“ISR”), a difficult-to-treat and serious complication of coronary stenting, currently expected to start before the end of 2023Strategic partnership with Terumo Corporation (“Terumo”) targets coronary ISR and multiple additional vascular indicat